Laboratoires Thea acquires insert from Carl Zeiss Meditec
Laboratoires Thea has acquired from Carl Zeiss Meditec a mydriatic ophthalmic insert (Mydriasert) indicated for dilated fundus examination or cataract surgery.
Clermont-Ferrand, France-Laboratoires Thea has acquired from Carl Zeiss Meditec a mydriatic ophthalmic insert (Mydriasert) indicated for dilated fundus examination or cataract surgery.
The agreement includes the acquisition of the production site of the insert in La Rochelle, France, along with relevant staff.
“This acquisition represents a significant addition to our product range and is completely in line with our strategy to become a leading provider of ophthalmic products,” said Jean-Frederic Chibret, Laboratoires Thea chief operating officer.
This device, shaped like an oblong tablet, is applied beneath the eyelid and disperses phenylephrine hydrochloride and tropicamide. The alpha-sympathomimetic activity of phenylephrine induces an increase in pupil diameter, and the anti-cholinergic activity of tropicamide prevents the iris from contracting, according to the company.
